Macrobian-Biotech (http://www.macrobian-biotech.com) was founded in May 2017 by Dr. Lars van der Heide, Prof. Dr. Marten smidt, and the UvA-Holding. Its primary goal is to perform pre-clinical research that leads to novel treatments for disorders of the midbrain dopamine system. Research at Macrobian-Biotech is performed within the Swammerdam Institute of Life Sciences at the University of Amsterdam (http://sils.uva.nl/), ensuring an excellent research climate.